Life Science Nation Newsletter | November 8, 2018 | Issue 291


  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI JPM 2019
  Life Science Investor Mandates  (Nov. 1 - Nov. 7 )
Seeks Oncology & Diabetes-Related Technologies, with Strongest Interests in Devices and Diagnostics
Actively Seeking New Therapeutics & Medical Device Investment Opportunities in the USA
Invests in Breakthrough Therapeutics with Established Proof-of-Concept & Devices with Clear Path to Commercialization, and Digital Health
Makes Strategic Investments in Early-Stage Medtech, Diagnostic, and Digital Health Technologies
News
LSN Services
LSN Videos
LSN Media Partners
By Karen Deyo, Investor Research Analyst, LSN

This past Monday, November 5th, at RESI NYC, all attendees, including scientist-entrepreneurs, investors and service providers, walked through the exhibit hall at the Midtown Hilton where the Innovation Challenge was taking place. The 30 finalists participating displayed their technologies, spanning from therapeutics to medical devices, diagnostics and digital health. These finalists were selected based on how investable they are, with criteria evaluating both innovation and commercial viability. We wish success to all of the finalists, but we offer congratulations to the 3 winning companies.


Lucy Parkinson. VP of Investor Research. Life Science Nation | Amit Vohra, CEO & President, Promaxo | Dinesh Kumar, Chief Operations Officer, Promaxo | Dennis Ford, Founder & CEO, Life Science Nation


Lucy Parkinson, VP of Investor Research, Life Science Nation | Rich Mager, CEO, Keriton | Dennis Ford, Founder & CEO, Life Science Nation

Lucy Parkinson, VP of Investor Research, Life Science Nation | Stephen Popielarski, CEO & Co-founder, Thermaquil | Dennis Ford, Founder & CEO, Life Science Nation



Created & Produced by